Table 1 Patient characteristics (n = 156)

Age, years (mean ± SD)

65.6 ± 10.8

65.3 ± 10.9

66.5 ± 10.3

0.645

Male, n (%)

114 (73.1%)

93 (74.4%)

21 (67.7%)

0.500

Underlying disease^a

 Malignancy

126 (80.8%)

101 (80.8%)

25 (80.6%)

1.000

 Hepatocellular carcinoma

49 (31.4%)

43 (34.4%)

6 (19.4%)

−

 Pancreatic cancer

24 (15.4%)

20 (16.0%)

4 (12.9%)

−

 Cholangiocarcinoma

11 (7.1%)

5 (4.0%)

6 (19.4%)

−

 Other cancers

42 (26.9%)

33 (26.4%)

9 (29.0%)

−

 Diabetes mellitus

40 (25.6%)

33 (26.4%)

7 (22.6%)

0.819

 Chronic hepatitis/liver cirrhosis

21 (13.5%)

18 (14.4%)

3 (9.7%)

0.769

 Chronic kidney disease

3 (1.9%)

2 (1.6%)

1 (3.2%)

0.488

 Other diseases

30 (19.2%)

24 (19.2%)

6 (19.4%)

1.000

 Immunosuppressive drug use (yes)

8 (5.1%)

6 (4.8%)

2 (6.5%)

0.659

 qSOFA score point (mean and range)

0.2 (0–3)

0.1 (0–1)

0.5 (0–3)

< 0.001

 Body temperature, °C (mean ± SD)

36.8 ± 0.8

36.6 ± 0.5

37.7 ± 1.1

< 0.001

 Skin redness at the insertion site

5 (3.2%)

0 (0%)

5 (16.1%)

< 0.001

Insertion site of CVC

 Jugular

148 (94.9%)

120 (96.0%)

28 (90.3%)

0.196

 Femoral

3 (1.9%)

2 (1.6%)

1 (3.2%)

0.488

 Peripherally inserted CVC

5 (3.2%)

3 (2.4%)

2 (6.5%)

0.259

Number of lumen

 3

103 (66.0%)

84 (67.2%)

19 (61.3%)

0.533

 2

48 (30.8%)

38 (30.4%)

10 (32.3%)

0.831

 1

5 (3.2%)

3 (2.4%)

2 (6.5%)

0.259

Primary purpose for CVC insertion

 Perioperative

141 (90.4%)

114 (91.2%)

27 (87.1%)

0.500

 Parenteral nutrition

9 (5.8%)

6 (4.8%)

3 (9.7%)

0.383

 Intensive care

6 (3.8%)

5 (4.0%)

1 (3.2%)

1.000

 Duration of catheterization, days (mean ± SD)

9.5 ± 9.0

9.0 ± 8.0

11.5 ± 12.2

0.600

 Antibiotic use during the catheterization

153 (98.1%)

123 (98.4%)

30 (96.8%)

0.488

 Antibiotic use after the removal

47 (30.1%)

22 (17.6%)

25 (80.6%)

< 0.001

 Defervescence time from the catheter removal, day (mean ± SD)

0.8 ± 2.4

0.3 ± 0.6

3.4 ± 4.5

< 0.001